Caitrin W. McDonough

Caitrin W. McDonough

Auto-generated profile, based on publicly available information

Caitrin W. McDonough

Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy University of Florida Gainesville Florida USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SSStefan J Schunk
Stefan J Schunk
MKMarcus E. Kleber
Marcus E. Kleber
WMWinfried März
Winfried März
SPShichao Pang
Shichao Pang
SZStephen Zewinger
Stephen Zewinger
BCBIOS consortium
BIOS consortium
Inflammation plays an important role in cardiovascular disease (CVD) development. The NOD-like receptor protein-3 (NLRP3) inflammasome contributes to the development of atherosclerosis in animal models. Components of the NLRP3 inflammasome pathway such as interleukin-1β can therapeutically be targeted. Associations of genetically determined inflammasome-mediated systemic inflammation with CVD and mortality in humans are unknown. We explored the association of genetic NLRP3 variants with prevalent CVD and cardiovascular mortality in 538 167 subjects on the individual participant level in an explorative gene-centric approach without performing multiple testing. Functional relevance of single-nucleotide polymorphisms on NLRP3 inflammasome activation has been evaluated in monocyte-enriched peripheral blood mononuclear cells (PBMCs). Genetic analyses identified the highly prevalent (minor allele frequency 39.9%) intronic NLRP3 variant rs10754555 to affect NLRP3 gene expression. rs10754555 carriers showed significantly higher C-reactive protein and serum amyloid A plasma levels. Carriers of the G allele showed higher NLRP3 inflammasome activation in isolated human PBMCs. In carriers of the rs10754555 variant, the prevalence of coronary artery disease was significantly higher as compared to non-carriers with a significant interaction between rs10754555 and age. Importantly, rs10754555 carriers had significantly higher risk for cardiovascular mortality during follow-up. Inflammasome inducers (e.g. urate, triglycerides, apolipoprotein C3) modulated the association between rs10754555 and mortality. The NLRP3 intronic variant rs10754555 is associated with increased systemic inflammation, inflammasome activation, prevalent coronary artery disease, and mortality. This study provides evidence for a substantial role of genetically driven systemic inflammation in CVD and highlights the NLRP3 inflammasome as a therapeutic target. rs10754555 associates with higher NLRP3 mRNA expression and NLRP3 inflammasome activation, which induces the release of IL-1β and IL-18. This leads to systemic inflammation, higher risk for coronary artery disease, and cardiovascular mortality.

15 June 2015 in Journal of the American Heart Association
Verified
Journal Article
Open access
CMCaitrin W. McDonough
Caitrin W. McDonough
LMLeslie A. McClure
Leslie A. McClure
BMBraxton D. Mitchell
Braxton D. Mitchell
YGYan Gong
Yan Gong
RHRichard B. Horenstein
Richard B. Horenstein
ASAlan R. Shuldiner
Alan R. Shuldiner
Background: The role of the CYP 2C19 genotype on clopidogrel efficacy has been studied widely, with data suggesting reduced clopidogrel efficacy in loss‐of‐function variant carriers taking clopidogrel after percutaneous coronary intervention; however, data are limited regarding the association between CYP 2C19 genetic variants and outcomes in stroke patients. We investigated whether CYP 2C19 metabolizer status affects the risk of recurrent stroke or major bleeding in subcortical stroke patients taking dual antiplatelet therapy with aspirin and clopidogrel. Methods and Results: CYP 2C19*2 and CYP 2C19*17 were genotyped in 522 patients treated with dual antiplatelet therapy from the Secondary Prevention of Small Subcortical Strokes ( SPS 3) study. CYP 2C19 metabolizer status was inferred from genotype, and associations with the risk of recurrent stroke and major bleeding were assessed in the overall cohort and by race/ethnic group with logistic regression modeling. In the overall cohort, there were no differences in outcomes by CYP 2C19 metabolizer status (recurrent stroke, odds ratio 1.81 [95% CI 0.76 to 4.30]; major bleeding, odds ratio 0.67 [95% CI 0.22 to 2.03]). In white participants, those with CYP 2C19 intermediate or poor metabolizer status had higher odds of recurrent stroke (odds ratio 5.19 [95% CI 1.08 to 24.90]) than those with extensive or ultrarapid metabolizer status, but there was no evidence of difference in major bleeding. Conclusions: There were significant differences in recurrent stroke by CYP2C19 genotype‐inferred metabolizer status in white subcortical stroke patients receiving dual antiplatelet therapy with aspirin and clopidogrel, consistent with cardiovascular studies on CYP 2C19 and clopidogrel; however, the bleeding risk that led to early termination of the antiplatelet arm of the SPS 3 trial does not appear to be explained by CYP 2C19 genotype. This study was relatively underpowered; therefore, these findings should be interpreted with caution and warrant replication. Clinical Trial Registration: URL : www.clinicaltrials.gov . Unique identifier: NCT 00059306.

2 May 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
CTCameron D. Thomas
Cameron D. Thomas
FFFrancesco Franchi
Francesco Franchi
EKEllen C. Keeley
Ellen C. Keeley
JRJoseph S. Rossi
Joseph S. Rossi
MWMarshall Winget
Marshall Winget
LCLarisa H. Cavallari
Larisa H. Cavallari
The Age, Body mass index, Chronic kidney disease, Diabetes mellitus, and CYP2C19 GENEtic variants (ABCD‐GENE) score was developed to identify patients at risk for diminished antiplatelet effects with clopidogrel after percutaneous coronary intervention (PCI). The objective of this study was to validate the ability of the ABCD‐GENE score to predict the risk for atherothrombotic events in a diverse, real‐world population of clopidogrel‐treated patients who underwent PCI and received clinical CYP2C19 genotyping to guide antiplatelet therapy. A total of 2,341 adult patients who underwent PCI, were genotyped for CYP2C19, and received treatment with clopidogrel across four institutions were included (mean age 64 ± 12 years, 35% women, and 20% Black). The primary outcome was major atherothrombotic events, defined as the composite of all‐cause death, myocardial infarction, ischemic stroke, stent thrombosis, or revascularization for unstable angina within 12 months following PCI. Major adverse cardiovascular events (MACE), defined as the composite of cardiovascular death, myocardial infarction, ischemic stroke, or stent thrombosis, was assessed as the secondary outcome. Outcomes were compared between patients with an ABCD‐GENE score ≥ 10 vs. < 10. The risk of major atherothrombotic events was higher in patients with an ABCD‐GENE score ≥ 10 (n = 505) vs. < 10 (n = 1,836; 24.6 vs. 14.7 events per 100 patient‐years, adjusted hazard ratio (HR) 1.66, 95% confidence interval (CI), 1.23–2.25, P < 0.001). The risk for MACE was also higher among patients with a score ≥ 10 vs. < 10 (16.7 vs. 10.1 events per 100 patient‐years, adjusted HR 1.59, 95% CI 1.11–2.30, P = 0.013). Our diverse, real‐world data demonstrate diminished clopidogrel effectiveness in post‐PCI patients with an ABCD‐GENE score ≥ 10.

26 May 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
NNNoor Ahmed Nahid
Noor Ahmed Nahid
CMCaitrin W. McDonough
Caitrin W. McDonough
YWYu‐Jung Jenny Wei
Yu‐Jung Jenny Wei
ECEmily J Cicali
Emily J Cicali
YGYan Gong
Yan Gong
JJJulie A. Johnson
Julie A. Johnson

26 August 2020 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
CMCaitrin W. McDonough
Caitrin W. McDonough
KBKyle Babcock
Kyle Babcock
KCKristen Chucri
Kristen Chucri
DCDana C. Crawford
Dana C. Crawford
JBJiang Bian
Jiang Bian
WHWilliam R. Hogan
William R. Hogan

15 August 2021 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
CMCaitrin W. McDonough
Caitrin W. McDonough
HWHelen R. Warren
Helen R. Warren
JJJohn R. Jack
John R. Jack
AMAlison A. Motsinger‐Reif
Alison A. Motsinger‐Reif
NANicole D. Armstrong
Nicole D. Armstrong
RCRhonda M. Cooper‐DeHoff
Rhonda M. Cooper‐DeHoff